The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.
Standard
The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. / Eiermann, W; Rezai, M; Kümmel, S; Kühn, T; Warm, M; Friedrichs, K; Schneeweiss, A; Markmann, S; Eggemann, H; Hilfrich, J; Jackisch, C; Witzel, Isabell; Eidtmann, H; Bachinger, A; Hell, S; Blohmer, J.
in: ANN ONCOL, Jahrgang 24, Nr. 3, 3, 2013, S. 618-624.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.
AU - Eiermann, W
AU - Rezai, M
AU - Kümmel, S
AU - Kühn, T
AU - Warm, M
AU - Friedrichs, K
AU - Schneeweiss, A
AU - Markmann, S
AU - Eggemann, H
AU - Hilfrich, J
AU - Jackisch, C
AU - Witzel, Isabell
AU - Eidtmann, H
AU - Bachinger, A
AU - Hell, S
AU - Blohmer, J
PY - 2013
Y1 - 2013
N2 - We carried out a prospective clinical study to evaluate the impact of the Recurrence Score (RS) on treatment decisions in early breast cancer (EBC).
AB - We carried out a prospective clinical study to evaluate the impact of the Recurrence Score (RS) on treatment decisions in early breast cancer (EBC).
M3 - SCORING: Journal article
VL - 24
SP - 618
EP - 624
JO - ANN ONCOL
JF - ANN ONCOL
SN - 0923-7534
IS - 3
M1 - 3
ER -